Edwards Jessie K, Cole Stephen R, Lesko Catherine R, Mathews W Christopher, Moore Richard D, Mugavero Michael J, Westreich Daniel
Am J Epidemiol. 2016 Aug 15;184(4):336-44. doi: 10.1093/aje/kwv339. Epub 2016 Jul 28.
Traditional epidemiologic approaches allow us to compare counterfactual outcomes under 2 exposure distributions, usually 100% exposed and 100% unexposed. However, to estimate the population health effect of a proposed intervention, one may wish to compare factual outcomes under the observed exposure distribution to counterfactual outcomes under the exposure distribution produced by an intervention. Here, we used inverse probability weights to compare the 5-year mortality risk under observed antiretroviral therapy treatment plans to the 5-year mortality risk that would had been observed under an intervention in which all patients initiated therapy immediately upon entry into care among patients positive for human immunodeficiency virus in the US Centers for AIDS Research Network of Integrated Clinical Systems multisite cohort study between 1998 and 2013. Therapy-naïve patients (n = 14,700) were followed from entry into care until death, loss to follow-up, or censoring at 5 years or on December 31, 2013. The 5-year cumulative incidence of mortality was 11.65% under observed treatment plans and 10.10% under the intervention, yielding a risk difference of -1.57% (95% confidence interval: -3.08, -0.06). Comparing outcomes under the intervention with outcomes under observed treatment plans provides meaningful information about the potential consequences of new US guidelines to treat all patients with human immunodeficiency virus regardless of CD4 cell count under actual clinical conditions.
传统的流行病学方法使我们能够比较两种暴露分布下的反事实结果,通常是100%暴露和100%未暴露。然而,为了估计一项拟议干预措施对人群健康的影响,人们可能希望将观察到的暴露分布下的事实结果与干预措施产生的暴露分布下的反事实结果进行比较。在此,我们使用逆概率权重,将美国综合临床系统艾滋病研究网络多中心队列研究中1998年至2013年期间人类免疫缺陷病毒呈阳性的患者在观察到的抗逆转录病毒治疗方案下的5年死亡风险,与在所有患者进入护理后立即开始治疗的干预措施下本应观察到的5年死亡风险进行比较。从未接受过治疗的患者(n = 14700)从进入护理开始随访,直至死亡、失访或在5年时或2013年12月31日被截尾。在观察到的治疗方案下,5年累积死亡率为11.65%,在干预措施下为10.10%,风险差为-1.57%(95%置信区间:-3.08,-0.06)。将干预措施下的结果与观察到的治疗方案下的结果进行比较,可为美国新指南在实际临床条件下治疗所有人类免疫缺陷病毒患者(无论CD4细胞计数如何)的潜在后果提供有意义的信息。